Multitarget inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently.
Wang, W., Wang, X., Tang, G., Zhu, C., Xiang, M., Xiao, Q., Zhang, Z.M., Gao, L., Yao, S.Q.(2023) Chem Commun (Camb) 59: 10789-10792
- PubMed: 37594149 
- DOI: https://doi.org/10.1039/d3cc03530a
- Primary Citation of Related Structures:  
8JMX - PubMed Abstract: 
Herein, we report a salicylaldehyde-based, reversible covalent inhibitor (A2) that possesses moderate cellular activity against AURKA with a prolonged residence time and shows significant non-covalent inhibition towards LRRK2. Our results indicated that this multitarget kinase inhibitor may be used as the starting point for future development of more potent, selective and dual-targeting covalent kinase inhibitors against AURKA and LRRK2 for mitophagy.
Organizational Affiliation: 
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518000, China. gaolq@mail.sysu.edu.cn.